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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and 
related documents* 
Section/item Item
No 
Description  Addressed on page 
number 
 
 
Administrative information  
Title 1 Descriptive title identifying the study design, 
population, interventions, and, if applicable, trial 
acronym 
1, 2 
Trial registration 2a Trial identifier and registry name. If not yet 
registered, name of intended registry 
2 
2b All items from the World Health Organization Trial 
Registration Data Set 
N/A 
Protocol version 3 Date and version identifier N/A 
Funding 4 Sources and types of financial, material, and other 
support 
19 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol 
contributors 
19 
5b Name and contact information for the trial sponsor Anne Marie Downey,  
Joint Research Office 
University College London 
 5c Role of study sponsor and funders, if any, in study 
design; collection, management, analysis, and 
interpretation of data; writing of the report; and the 
decision to submit the report for publication, 
including whether they will have ultimate authority 
over any of these activities 
Funders gave input into  
Design, sponsor will review 
Before publication, in line  
With UCL publication policy 
 5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, endpoint 
adjudication committee, data management team, 
and other individuals or groups overseeing the trial, 
if applicable (see Item 21a for data monitoring 
committee) 
In protocol, study has a  
TMG and TSC as well as  
IDMC.  
 2 
Introduction    
Background and 
rationale 
6a Description of research question and justification 
for undertaking the trial, including summary of 
relevant studies (published and unpublished) 
examining benefits and harms for each intervention 
3-5 
 6b Explanation for choice of comparators 5 
Objectives 7 Specific objectives or hypotheses 5 
Trial design 8 Description of trial design including type of trial (eg, 
parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, 
equivalence, noninferiority, exploratory) 
5 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, 
academic hospital) and list of countries where data 
will be collected. Reference to where list of study 
sites can be obtained 
5 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If 
applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, 
surgeons, psychotherapists) 
5-8 
Interventions 11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will 
be administered 
10-11 
11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, drug 
dose change in response to harms, participant 
request, or improving/worsening disease) 
16 
11c Strategies to improve adherence to intervention 
protocols, and any procedures for monitoring 
adherence (eg, drug tablet return, laboratory tests) 
N/A 
11d Relevant concomitant care and interventions that 
are permitted or prohibited during the trial 
In protocol, any, will 
be recorded 
Outcomes 12 Primary, secondary, and other outcomes, including 
the specific measurement variable (eg, systolic 
blood pressure), analysis metric (eg, change from 
baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time 
point for each outcome. Explanation of the clinical 
relevance of chosen efficacy and harm outcomes is 
strongly recommended 
14 
 3 
Participant 
timeline 
13 Time schedule of enrolment, interventions 
(including any run-ins and washouts), 
assessments, and visits for participants. A 
schematic diagram is highly recommended (see 
Figure) 
9-12 
Sample size 14 Estimated number of participants needed to 
achieve study objectives and how it was 
determined, including clinical and statistical 
assumptions supporting any sample size 
calculations 
12-13 
Recruitment 15 Strategies for achieving adequate participant 
enrolment to reach target sample size 
13 
Methods: Assignment of interventions (for controlled trials)  
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, 
computer-generated random numbers), and list of 
any factors for stratification. To reduce predictability 
of a random sequence, details of any planned 
restriction (eg, blocking) should be provided in a 
separate document that is unavailable to those who 
enrol participants or assign interventions 
8-9 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation 
sequence (eg, central telephone; sequentially 
numbered, opaque, sealed envelopes), describing 
any steps to conceal the sequence until 
interventions are assigned 
8-9 
Implementation 16c Who will generate the allocation sequence, who will 
enrol participants, and who will assign participants 
to interventions 
8-9 
Blinding 
(masking) 
17a Who will be blinded after assignment to 
interventions (eg, trial participants, care providers, 
outcome assessors, data analysts), and how 
9 
 17b If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a 
participant’s allocated intervention during the trial 
9 
Methods: Data collection, management, and analysis  
 4 
Data collection 
methods 
18a Plans for assessment and collection of outcome, 
baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate 
measurements, training of assessors) and a 
description of study instruments (eg, 
questionnaires, laboratory tests) along with their 
reliability and validity, if known. Reference to where 
data collection forms can be found, if not in the 
protocol 
Throughout manuscript 
 18b Plans to promote participant retention and 
complete follow-up, including list of any outcome 
data to be collected for participants who 
discontinue or deviate from intervention protocols 
16-17 
Data 
management 
19 Plans for data entry, coding, security, and storage, 
including any related processes to promote data 
quality (eg, double data entry; range checks for 
data values). Reference to where details of data 
management procedures can be found, if not in the 
protocol 
13-14 
Statistical 
methods 
20a Statistical methods for analysing primary and 
secondary outcomes. Reference to where other 
details of the statistical analysis plan can be found, 
if not in the protocol 
15-16 
 20b Methods for any additional analyses (eg, subgroup 
and adjusted analyses) 
15-16 
 20c Definition of analysis population relating to protocol 
non-adherence (eg, as randomised analysis), and 
any statistical methods to handle missing data (eg, 
multiple imputation) 
15-17 
Methods: Monitoring  
Data monitoring 21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; 
statement of whether it is independent from the 
sponsor and competing interests; and reference to 
where further details about its charter can be found, 
if not in the protocol. Alternatively, an explanation 
of why a DMC is not needed 
Independent committee 
from sponsor and trial team 
charter in TMF and on 
UCL JRO website 
 5 
 21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to 
terminate the trial 
Interim analyses by  
statistician after 24 patients 
in trial to assess tolerability 
funder has decision to  
terminate trial if ketamine  
associated with much greater  
drop-out 
Harms 22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously reported 
adverse events and other unintended effects of trial 
interventions or trial conduct 
Collected in case report  
forms, reported in full  
protocol pages 56 - 61 
Auditing 23 Frequency and procedures for auditing trial 
conduct, if any, and whether the process will be 
independent from investigators and the sponsor 
N/A 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics 
committee/institutional review board (REC/IRB) 
approval 
Approved 
Protocol 
amendments 
25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
See full protocol section 16  
page 70 
Consent or assent 26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, 
and how (see Item 32) 
Medically qualified staff  
at site 
 26b Additional consent provisions for collection and use 
of participant data and biological specimens in 
ancillary studies, if applicable 
N/A 
Confidentiality 27 How personal information about potential and 
enrolled participants will be collected, shared, and 
maintained in order to protect confidentiality before, 
during, and after the trial 
13-14 
Declaration of 
interests 
28 Financial and other competing interests for 
principal investigators for the overall trial and each 
study site 
N/A  
Access to data 29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements 
that limit such access for investigators 
The trial team will have  
access to the final dataset 
 6 
Ancillary and 
post-trial care 
30 Provisions, if any, for ancillary and post-trial care, 
and for compensation to those who suffer harm 
from trial participation 
Insurance as per UCL  
JRO standard procedures 
(full protocol p. 70) 
Dissemination 
policy 
31a Plans for investigators and sponsor to 
communicate trial results to participants, healthcare 
professionals, the public, and other relevant groups 
(eg, via publication, reporting in results databases, 
or other data sharing arrangements), including any 
publication restrictions 
 All proposed  
publications will be  
discussed with Sponsor 
 prior to publishing  
other than those presented at scientific forums/meetings. Please refer 
to UCL publication policy. 
  
 31b Authorship eligibility guidelines and any intended 
use of professional writers 
N/A 
 31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical 
code 
Full protocol will 
be stored in online  
repository with dataset  
Appendices    
Informed consent 
materials 
32 Model consent form and other related 
documentation given to participants and authorised 
surrogates 
On trial website 
www.exeter.ac.uk/ 
psychology/kare 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and 
storage of biological specimens for genetic or 
molecular analysis in the current trial and for future 
use in ancillary studies, if applicable 
N/A 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license. 
 
